Jeffrey P. Mornhinweg

Array ( [id] => 17194195 [patent_doc_number] => 11162945 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-02 [patent_title] => Methods and compositions for detecting single T cell receptor affinity and sequence [patent_app_type] => utility [patent_app_number] => 16/092607 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 32 [patent_no_of_words] => 23806 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210727 [patent_doc_number] => 20190117748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => GLYCOSYLATED OLIGONUCLEOTIDES THAT MIMIC THE HIV-1 EPITOPE OF NEUTRALIZING MONOCLONAL ANTIBODY 2G12 [patent_app_type] => utility [patent_app_number] => 16/092137 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11962120 [patent_doc_number] => 20170266272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'TRANSGENIC VERO-CD4/CCR5 CELL LINE' [patent_app_type] => utility [patent_app_number] => 15/481108 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 44545 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17406063 [patent_doc_number] => 11246924 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform [patent_app_type] => utility [patent_app_number] => 16/090561 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 32 [patent_no_of_words] => 23445 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16090561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342111 [patent_doc_number] => 20190153028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => METHOD FOR PROTEIN PURIFICATION [patent_app_type] => utility [patent_app_number] => 16/089443 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13265383 [patent_doc_number] => 10144766 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-04 [patent_title] => Cytotoxic T Lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection [patent_app_type] => utility [patent_app_number] => 15/471098 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 4 [patent_no_of_words] => 8670 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15471098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16367825 [patent_doc_number] => 10799560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => HSV vectors for delivery of NT3 and treatment of CIPN [patent_app_type] => utility [patent_app_number] => 16/088408 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 124 [patent_figures_cnt] => 32 [patent_no_of_words] => 20176 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099291 [patent_doc_number] => 20190091321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => A COMBINATION VACCINE AGAINST PCV2 AND PRRS VIRUS INFECTION COMPRISING ALBUMIN [patent_app_type] => utility [patent_app_number] => 16/086629 [patent_app_country] => US [patent_app_date] => 2017-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428015 [patent_doc_number] => 20180265550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR FLAVIVIRUSES [patent_app_type] => utility [patent_app_number] => 15/464289 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15464289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13871623 [patent_doc_number] => 20190032152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => COMPOSITIONS AND METHODS FOR THE RAPID DIFFERENTIAL DETECTION OF ZIKA VIRUS [patent_app_type] => utility [patent_app_number] => 16/085825 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15913101 [patent_doc_number] => 10653772 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg [patent_app_type] => utility [patent_app_number] => 16/088169 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7014 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16383189 [patent_doc_number] => 10808011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-20 [patent_title] => Recombinant HIV-1 envelope proteins and their use [patent_app_type] => utility [patent_app_number] => 16/083359 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 30 [patent_no_of_words] => 30703 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11704649 [patent_doc_number] => 20170173148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'Treatment of Infection' [patent_app_type] => utility [patent_app_number] => 15/451698 [patent_app_country] => US [patent_app_date] => 2017-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7470 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15280025 [patent_doc_number] => 10512662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 16/079217 [patent_app_country] => US [patent_app_date] => 2017-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 14 [patent_no_of_words] => 19539 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141935 [patent_doc_number] => 10704032 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Retrovirus packaging cell [patent_app_type] => utility [patent_app_number] => 16/079940 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 11 [patent_no_of_words] => 16215 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13926233 [patent_doc_number] => 20190046632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => COMPOSITIONS AND METHODS FOR MAKING AND USING THERMOSTABLE IMMUNOGENIC FORMULATIONS WITH INCREASED COMPATIBILITY OF USE AS VACCINES AGAINST ONE OR MORE PATHOGENS [patent_app_type] => utility [patent_app_number] => 16/079507 [patent_app_country] => US [patent_app_date] => 2017-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15210401 [patent_doc_number] => 20190367887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => NOVEL VACCINIA VIRUS VECTORS RELATED TO MVA WITH EXTENSIVE GENOMIC SYMMETRIES [patent_app_type] => utility [patent_app_number] => 16/485748 [patent_app_country] => US [patent_app_date] => 2017-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16485748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963868 [patent_doc_number] => 20170268020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'MULTIGENOME RETROVIRAL VECTOR PREPARATIONS AND METHODS AND SYSTEMS FOR PRODUCING AND USING SAME' [patent_app_type] => utility [patent_app_number] => 15/439324 [patent_app_country] => US [patent_app_date] => 2017-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 30730 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15439324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12091342 [patent_doc_number] => 20170348433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/435212 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 47812 [patent_no_of_claims] => 78 [patent_no_of_ind_claims] => 61 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15435212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11668499 [patent_doc_number] => 20170157219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'METHODS OF TREATING ZIKA VIRUS, MERS-COV, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, AND RHINOVIRUS IN MAMMALIAN PATIENTS' [patent_app_type] => utility [patent_app_number] => 15/429046 [patent_app_country] => US [patent_app_date] => 2017-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 4234 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 32 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15429046 [rel_patent_id] =>[rel_patent_doc_number] =>)